NEW BRUNSWICK, N.J.,
Oct. 19, 2021 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced results
for third-quarter 2021. "Our third-quarter results demonstrate
solid performance across Johnson & Johnson, driven by robust
above-market results in Pharmaceuticals, ongoing recovery in
Medical Devices, and strong growth in Consumer Health," said
Alex Gorsky, Chairman and Chief
Executive Officer. "In the face of evolving marketplace dynamics
resulting from the effects of COVID-19 and other global trends, we
have continued to demonstrate the responsiveness and agility
required to meet the needs of our stakeholders, while also
successfully investing in a pipeline of innovation and key
commercial platforms to drive our future growth. I am incredibly
proud of our Company's transformative growth over the last decade.
As I prepare to transition the role of CEO to Joaquin Duato in January, I want to extend my
deepest gratitude to our colleagues around the globe who work
tirelessly to deliver solutions to address the world's most urgent
and unmet healthcare challenges."
OVERALL FINANCIAL
RESULTS
|
|
|
|
Q3
|
|
|
($ in Millions,
except EPS)
|
2021
|
2020
|
%
Change
|
Reported
Sales
|
$
23,338
|
$
21,082
|
10.7%
|
Net
Earnings
|
3,667
|
3,554
|
3.2%
|
EPS
(diluted)
|
$
1.37
|
$
1.33
|
3.0%
|
|
|
|
|
Q3
|
|
|
Non-GAAP*($ in
Millions, except EPS)
|
2021
|
2020
|
%
Change
|
Operational
Sales1,2
|
|
|
9.9%
|
Adjusted Operational
Sales1,3
|
|
|
10.6%
|
Adjusted Net
Earnings1,4
|
6,968
|
5,868
|
18.7%
|
Adjusted EPS
(diluted)1,4
|
$
2.60
|
$
2.20
|
18.2%
|
|
|
1
|
Non-GAAP financial
measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
|
2
|
Excludes the impact
of translational currency
|
3
|
Excludes the net
impact of acquisitions and divestitures and translational
currency
|
4
|
Excludes intangible
amortization expense and special items
|
REGIONAL SALES
RESULTS
|
|
Q3
|
|
%
Change
|
($ in
Millions)
|
2021
|
2020
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
U.S.
|
$
11,963
|
$
11,086
|
7.9%
|
7.9
|
-
|
8.0
|
International
|
11,375
|
9,996
|
13.8%
|
12.1
|
1.7
|
13.5
|
Worldwide
|
$
23,338
|
$
21,082
|
10.7%
|
9.9
|
0.8
|
10.6
|
|
|
1
|
Non-GAAP financial
measure; refer to reconciliations of non-GAAP financial measures
included in accompanying schedules
|
2
|
Excludes the impact
of translational currency
|
3
|
Excludes the net
impact of acquisitions and divestitures and translational
currency
|
|
Note: values may have
been rounded
|
SEGMENT SALES
RESULTS
|
|
Q3
|
|
%
Change
|
($ in
Millions)
|
2021
|
2020
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
Consumer
Health
|
$
3,700
|
$
3,514
|
5.3%
|
4.1
|
1.2
|
5.7
|
Pharmaceutical
|
12,994
|
11,418
|
13.8%
|
13.2
|
0.6
|
13.8
|
Medical
Devices
|
6,644
|
6,150
|
8.0%
|
7.0
|
1.0
|
7.6
|
Worldwide
|
$
23,338
|
$
21,082
|
10.7%
|
9.9
|
0.8
|
10.6
|
|
|
1
|
Non-GAAP financial
measure; refer to reconciliations of non-GAAP financial measures
included in accompanying schedules
|
2
|
Excludes the impact
of translational currency
|
3
|
Excludes the net
impact of acquisitions and divestitures and translational
currency
|
|
Note: values may have
been rounded
|
THIRD QUARTER 2021 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational
sales, excluding the net impact of acquisitions and divestitures,
increased 5.7%* primarily driven by over-the-counter (OTC)
products. Major contributors to growth were TYLENOL and MOTRIN
analgesics, upper respiratory products, and digestive health in
OTC, and AVEENO in Skin Health / Beauty.
Pharmaceutical
Pharmaceutical worldwide operational
sales, excluding the net impact of acquisitions and divestitures,
grew 13.8%* driven by DARZALEX (daratumumab), for the treatment of
multiple myeloma, STELARA (ustekinumab), a biologic for the
treatment of a number of immune-mediated inflammatory diseases,
TREMFYA (guselkumab), a biologic for the treatment of adults living
with moderate to severe plaque psoriasis, and for adults with
active psoriatic arthritis, ERLEADA (apalutamide), a
next-generation androgen receptor inhibitor for the treatment of
patients with prostate cancer, INVEGA SUSTENNA/XEPLION/INVEGA
TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable
atypical antipsychotics for the treatment of schizophrenia in
adults, and OPSUMIT (macitentan) an oral endothelin receptor
antagonist indicated for the treatment of pulmonary arterial
hypertension to delay disease progression. Also contributing to
growth was sales of the not-for-profit COVID-19 Vaccine
(Ad26.COV2.S) for the treatment of the SARS-CoV-2 virus. This
growth was partially offset by declines in U.S. sales of REMICADE
(infliximab), a biologic approved for the treatment of a number of
immune-mediated inflammatory diseases, and INVOKANA (canagliflozin)
for the treatment of adults with type 2 diabetes.
Medical Devices
Medical Devices worldwide operational
sales, excluding the net impact of acquisitions and divestitures,
grew 7.6%*, driven by electrophysiology products in Interventional
Solutions, wound closure products in General Surgery, surgical
vision products and contact lenses in Vision, trauma, hips, and
knees in Orthopaedics, and energy, endocutters, and biosurgicals in
Advanced Surgery. Growth was partially offset by Spine, Sports
& Other.
NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The
information contained in this section should be read in conjunction
with Johnson & Johnson's other disclosures filed with the
Securities and Exchange Commission, including its Current Reports
on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on
Form 10-K. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. The reader is also encouraged to review all other news
releases available online in the Investors section of the company's
website at news releases.
Regulatory
Decisions
|
INVEGA HAFYERA
(paliperidone palmitate) Receives FDA Approval For First and Only
Twice-Yearly Treatment for Adults with Schizophrenia
|
(press
release)
|
XARELTO (rivaroxaban)
Plus Aspirin Receives FDA Approval For Expanded Peripheral Artery
Disease (PAD) Indication to Include Patients After Lower-Extremity
Revascularization (LER)
|
(press
release)
|
UPTRAVI (selexipag)
Receives FDA Approval For Intravenous Use in Adult Patients with
Pulmonary Arterial Hypertension (PAH)
|
(press
release)
|
Regulatory
Submissions
|
Johnson & Johnson
Announces Submission of Emergency Use Authorization Amendment to
the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
1
|
(press
release)
|
Janssen Submits
Application Seeking U.S. FDA Approval of STELARA (ustekinumab) for
the Treatment of Pediatric Patients With Juvenile Psoriatic
Arthritis 1
|
(press
release)
|
Other
|
Alex Gorsky to
Transition Role of Chief Executive Officer of Johnson & Johnson
to Joaquin Duato, Effective January 3, 2022
|
(press
release)
|
Dr. Paul Stoffels,
Vice Chairman of the Executive Committee and Chief Scientific
Officer of Johnson & Johnson to Retire, Effective December 31,
2021 1
|
(press
release)
|
Johnson & Johnson
Announces Real-World Evidence and Phase 3 Data Confirming Strong
and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the
U.S.
|
(press
release)
|
Johnson & Johnson
Issues Statement on Nationwide Opioid Settlement
Agreement
|
(press
release)
|
DePuy Synthes
Announces Introduction of the INHANCE Shoulder System, a
First-to-Market, Fully Integrated Shoulder Arthroplasty
System
|
(press
release)
|
Janssen Announces
Start of Phase 3 Trial for Investigational Respiratory Syncytial
Virus (RSV) Vaccine in Older Adults
|
(press
release)
|
Janssen Receives
Positive CHMP Opinion for BYANNLI (six-monthly paliperidone
palmitate) for the Maintenance Treatment of Schizophrenia in
Adults
|
(press
release)
|
Ethicon Announces
ECHELON CIRCULAR Powered Stapler Associated with Major Reduction in
Serious Complications Following Colorectal Surgery
|
(press
release)
|
Johnson & Johnson
Takes Steps to Equitably Resolve All Current and Future Talc Claims
1
|
(press
release)
|
Janssen Receives
Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment
of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon
20 Insertion Mutations After Failure of Platinum-Based Therapy
1
|
(press
release)
|
Johnson & Johnson
COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency
Use Authorization by U.S. FDA Advisory Committee
1
|
(press
release)
|
1Subsequent to the quarter
|
FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does
not provide GAAP financial measures on a forward-looking basis
because the company is unable to predict with reasonable certainty
the ultimate outcome of legal proceedings, unusual gains and
losses, acquisition-related expenses and purchase accounting fair
value adjustments without unreasonable effort. These items are
uncertain, depend on various factors, and could be material to
Johnson & Johnson's results computed in accordance with
GAAP.
($ in Billions,
except EPS)
|
October 2021
(Base Business)
|
October
2021
(incl. COVID
Vx)
|
July
2021
(Base
Business)
|
July
2021
(incl. COVID
Vx)
|
Adjusted
Operational
Sales1,2
Change vs. Prior
Year
|
9.9% -
10.5%
|
12.9% -
13.5%
|
9.5% -
10.5%
|
12.5% -
13.5%
|
Operational
Sales2
Change vs. Prior
Year
|
$90.3B –
90.8B
9.4% –
10.0%
|
$92.8 -
$93.3B
12.4% –
13.0%
|
$90.0B -
$90.8B
9.0% –
10.0%
|
$92.5B -
$93.3B
12.0% –
13.0%
|
Estimated
Reported
Sales3
Change vs. Prior
Year
|
$91.6B -
$92.1B
10.9% –
11.5%
|
$94.1B -
$94.6B
13.9% –
14.5%
|
$91.3B -
$92.1B
10.5% –
11.5%
|
$93.8B -
$94.6B
13.5% –
14.5%
|
|
|
|
|
|
Adjusted Operational
EPS
(Diluted)2,4
Change vs. Prior
Year
|
|
$9.65 -
$9.70
20.2% -
20.8%
|
|
$9.50 -
$9.60
18.4% -
19.6%
|
Adjusted EPS
(Diluted)3,4
Change vs. Prior
Year
|
|
$9.77 -
$9.82
21.7% -
22.3%
|
|
$9.60 -
$9.70
19.6% -
20.8%
|
|
|
1
|
Non-GAAP financial
measure; excludes the net impact of acquisitions and
divestitures
|
2
|
Non-GAAP financial
measure; excludes the impact of translational currency
|
3
|
Calculated using Euro
Average Rate: July 2021 = $1.19 and October = $1.19 (Illustrative
purposes only)
|
4
|
Non-GAAP financial
measure; excludes intangible amortization expense and special
items
|
|
Note: % may have been
rounded
|
Other modeling considerations will be provided on the
webcast.
WEBCAST INFORMATION:
Johnson & Johnson will
conduct a conference call with investors to discuss this earnings
release today at 8:30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and
other interested parties may be accessed by visiting the Johnson
& Johnson website. A replay and podcast will be available
approximately two hours after the live webcast in the Investors
section of the company's website at
events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth
excluding the impact of translational currency, adjusted
operational sales growth excluding the net impact of acquisitions
and divestitures and translational currency, as well as adjusted
net earnings, adjusted diluted earnings per share and adjusted
operational diluted earnings per share excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures, reconciliations
of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying
financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings
release are available on the company's website at
quarterly-results. These schedules include supplementary sales
data, a condensed consolidated statement of earnings,
reconciliations of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson &
Johnson, including adjusted income before tax by segment, a
pharmaceutical pipeline of selected compounds in late stage
development and a copy of today's earnings call presentation can
also be found in the Investors section of the company's website at
quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS:
This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995 regarding, among other things: future operating and
financial performance, product development, market position and
business strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: risks related to the impact of the
COVID-19 global pandemic, such as the scope and duration of the
outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical
procedures, supply chain disruptions and other impacts to the
business, or on the Company's ability to execute business
continuity plans, as a result of the COVID-19 pandemic, economic
factors, such as interest rate and currency exchange rate
fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges inherent
in new product research and development, including uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of
commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans; the impact of
business combinations and divestitures; manufacturing difficulties
or delays, internally or within the supply chain; product efficacy
or safety concerns resulting in product recalls or regulatory
action; significant adverse litigation or government action,
including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global
health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health
care products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny
of the health care industry by government agencies. A further list
and descriptions of these risks, uncertainties and other factors
can be found in Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended January 3,
2021 including in the sections captioned "Cautionary Note
Regarding Forward-Looking Statements" and "Item 1A. Risk Factors,"
in the Company's most recently filed Quarterly Report on Form 10-Q
and the Company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Any forward-looking statement made in this release speaks
only as of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,625
|
|
1,556
|
|
4.5
|
%
|
4.5
|
|
-
|
|
$
4,987
|
|
4,853
|
|
2.8
|
%
|
2.8
|
|
-
|
International
|
2,075
|
|
1,958
|
|
5.9
|
|
3.7
|
|
2.2
|
|
5,991
|
|
5,582
|
|
7.3
|
|
3.5
|
|
3.8
|
|
3,700
|
|
3,514
|
|
5.3
|
|
4.1
|
|
1.2
|
|
10,978
|
|
10,435
|
|
5.2
|
|
3.1
|
|
2.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
7,221
|
|
6,438
|
|
12.2
|
|
12.2
|
|
-
|
|
20,536
|
|
18,619
|
|
10.3
|
|
10.3
|
|
-
|
International
|
5,773
|
|
4,980
|
|
15.9
|
|
14.6
|
|
1.3
|
|
17,256
|
|
14,685
|
|
17.5
|
|
12.5
|
|
5.0
|
|
12,994
|
|
11,418
|
|
13.8
|
|
13.2
|
|
0.6
|
|
37,792
|
|
33,304
|
|
13.5
|
|
11.3
|
|
2.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,117
|
|
3,092
|
|
0.8
|
|
0.8
|
|
-
|
|
9,470
|
|
7,852
|
|
20.6
|
|
20.6
|
|
-
|
International
|
3,527
|
|
3,058
|
|
15.4
|
|
13.3
|
|
2.1
|
|
10,731
|
|
8,518
|
|
26.0
|
|
20.5
|
|
5.5
|
|
6,644
|
|
6,150
|
|
8.0
|
|
7.0
|
|
1.0
|
|
20,201
|
|
16,370
|
|
23.4
|
|
20.5
|
|
2.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
11,963
|
|
11,086
|
|
7.9
|
|
7.9
|
|
-
|
|
34,993
|
|
31,324
|
|
11.7
|
|
11.7
|
|
-
|
International
|
11,375
|
|
9,996
|
|
13.8
|
|
12.1
|
|
1.7
|
|
33,978
|
|
28,785
|
|
18.0
|
|
13.1
|
|
4.9
|
Worldwide
|
$
23,338
|
|
21,082
|
|
10.7
|
%
|
9.9
|
|
0.8
|
|
$
68,971
|
|
60,109
|
|
14.7
|
%
|
12.4
|
|
2.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
|
Johnson &
Johnson and Subsidiaries
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
|
2021
|
|
2020
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
11,963
|
|
11,086
|
|
7.9
|
%
|
7.9
|
|
-
|
|
$
34,993
|
|
31,324
|
|
11.7
|
%
|
11.7
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
5,587
|
|
4,819
|
|
15.9
|
|
14.6
|
|
1.3
|
|
16,669
|
|
13,709
|
|
21.6
|
|
15.3
|
|
6.3
|
Western Hemisphere
excluding U.S.
|
1,500
|
|
1,296
|
|
15.7
|
|
13.4
|
|
2.3
|
|
4,291
|
|
3,931
|
|
9.2
|
|
8.1
|
|
1.1
|
Asia-Pacific,
Africa
|
4,288
|
|
3,881
|
|
10.5
|
|
8.5
|
|
2.0
|
|
13,018
|
|
11,145
|
|
16.8
|
|
12.3
|
|
4.5
|
International
|
11,375
|
|
9,996
|
|
13.8
|
|
12.1
|
|
1.7
|
|
33,978
|
|
28,785
|
|
18.0
|
|
13.1
|
|
4.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
23,338
|
|
21,082
|
|
10.7
|
%
|
9.9
|
|
0.8
|
|
$
68,971
|
|
60,109
|
|
14.7
|
%
|
12.4
|
|
2.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
|
Johnson &
Johnson and Subsidiaries
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
THIRD
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
23,338
|
|
100.0
|
|
$
21,082
|
|
100.0
|
|
10.7
|
Cost of products
sold
|
7,250
|
|
31.1
|
|
6,972
|
|
33.1
|
|
4.0
|
Gross
Profit
|
16,088
|
|
68.9
|
|
14,110
|
|
66.9
|
|
14.0
|
Selling, marketing
and administrative expenses
|
6,000
|
|
25.7
|
|
5,431
|
|
25.8
|
|
10.5
|
Research and
development expense
|
3,422
|
|
14.7
|
|
2,840
|
|
13.5
|
|
20.5
|
In-process
research and development
|
900
|
|
3.9
|
|
138
|
|
0.6
|
|
|
Interest (income)
expense, net
|
7
|
|
0.0
|
|
32
|
|
0.1
|
|
|
Other (income)
expense, net
|
1,850
|
|
7.9
|
|
1,200
|
|
5.7
|
|
|
Restructuring
|
60
|
|
0.2
|
|
68
|
|
0.3
|
|
|
Earnings before
provision for taxes on income
|
3,849
|
|
16.5
|
|
4,401
|
|
20.9
|
|
(12.5)
|
Provision for
taxes on income
|
182
|
|
0.8
|
|
847
|
|
4.0
|
|
(78.5)
|
Net
earnings
|
$
3,667
|
|
15.7
|
|
$
3,554
|
|
16.9
|
|
3.2
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.37
|
|
|
|
$
1.33
|
|
|
|
3.0
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,674.9
|
|
|
|
2,669.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
4.7
|
%
|
|
|
19.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
8,058
|
|
34.5
|
|
$
7,246
|
|
34.4
|
|
11.2
|
Net
earnings
|
$
6,968
|
|
29.9
|
|
$
5,868
|
|
27.8
|
|
18.7
|
Net earnings per
share (Diluted)
|
$
2.60
|
|
|
|
$
2.20
|
|
|
|
18.2
|
Effective tax
rate
|
13.5
|
%
|
|
|
19.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
Johnson &
Johnson and Subsidiaries
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
NINE
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
68,971
|
|
100.0
|
|
$
60,109
|
|
100.0
|
|
14.7
|
Cost of products
sold
|
21,900
|
|
31.8
|
|
20,613
|
|
34.3
|
|
6.2
|
Gross
Profit
|
47,071
|
|
68.2
|
|
39,496
|
|
65.7
|
|
19.2
|
Selling, marketing
and administrative expenses
|
17,505
|
|
25.4
|
|
15,627
|
|
26.0
|
|
12.0
|
Research and
development expense
|
9,994
|
|
14.5
|
|
8,127
|
|
13.5
|
|
23.0
|
In-process
research and development
|
900
|
|
1.3
|
|
144
|
|
0.3
|
|
|
Interest (income)
expense, net
|
83
|
|
0.1
|
|
16
|
|
0.0
|
|
|
Other (income)
expense, net
|
480
|
|
0.7
|
|
545
|
|
0.9
|
|
|
Restructuring
|
169
|
|
0.2
|
|
187
|
|
0.3
|
|
|
Earnings before
provision for taxes on income
|
17,940
|
|
26.0
|
|
14,850
|
|
24.7
|
|
20.8
|
Provision for
taxes on income
|
1,798
|
|
2.6
|
|
1,874
|
|
3.1
|
|
(4.1)
|
Net
earnings
|
$
16,142
|
|
23.4
|
|
$
12,976
|
|
21.6
|
|
24.4
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
6.04
|
|
|
|
$
4.86
|
|
|
|
24.3
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,674.6
|
|
|
|
2,670.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
10.0
|
%
|
|
|
12.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
24,125
|
|
35.0
|
|
$
19,827
|
|
33.0
|
|
21.7
|
Net
earnings
|
$
20,517
|
|
29.7
|
|
$
16,468
|
|
27.4
|
|
24.6
|
Net earnings per
share (Diluted)
|
$
7.67
|
|
|
|
$
6.17
|
|
|
|
24.3
|
Effective tax
rate
|
15.0
|
%
|
|
|
16.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
Johnson &
Johnson and Subsidiaries
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
Third
Quarter
|
|
Nine Months
Ended
|
|
(Dollars in Millions
Except Per Share Data)
|
2021
|
|
2020
|
|
2021
|
|
2020
|
|
Net Earnings, after
tax- as reported
|
$3,667
|
|
$3,554
|
|
$16,142
|
|
$12,976
|
|
|
|
|
|
|
|
|
|
|
Pre-tax
Adjustments
|
|
|
|
|
|
|
|
|
Intangible Asset
Amortization expense
|
1,159
|
|
1,181
|
|
3,576
|
|
3,426
|
|
Litigation expense,
net
|
2,077
|
|
1,477
|
|
2,054
|
|
2,210
|
|
IPR&D
|
900
|
|
138
|
|
900
|
|
144
|
|
Restructuring
related
|
121
|
|
130
|
|
333
|
|
363
|
|
Acquisition,
integration and divestiture related ¹
|
20
|
|
(154)
|
|
(504)
|
|
(1,087)
|
|
(Gains)/losses on
securities
|
(127)
|
|
32
|
|
(335)
|
|
(174)
|
|
Medical Device
Regulation
|
59
|
|
38
|
|
161
|
|
89
|
|
Other
|
-
|
|
3
|
|
-
|
|
6
|
|
|
|
|
|
|
|
|
|
|
Tax
Adjustments
|
|
|
|
|
|
|
|
|
Tax impact on special
item adjustments 2
|
(849)
|
|
(482)
|
|
(1,097)
|
|
(1,002)
|
|
Tax legislation and
related impacts
|
(59)
|
|
(49)
|
|
(713)
|
|
(483)
|
|
Adjusted Net
Earnings, after tax
|
$6,968
|
|
$5,868
|
|
$20,517
|
|
$16,468
|
|
Average shares
outstanding (Diluted)
|
2,674.9
|
|
2,669.3
|
|
2,674.6
|
|
2,670.8
|
|
Adjusted net earnings
per share (Diluted)
|
$2.60
|
|
$2.20
|
|
$7.67
|
|
$6.17
|
|
Operational adjusted
net earnings per share (Diluted)
|
$2.56
|
|
|
|
$7.47
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
|
|
|
1
|
Acquisition,
integration and divestiture related for the nine months of 2021
primarily includes the gain on the divestiture of two
Pharmaceutical brands outside of the U.S. Acquisition,
integration and divestiture related for 2020 primarily includes a
Contingent Consideration reversal ($165M in third quarter and
$1,148M in nine months) related to the timing of certain
developmental milestones associated with the Auris Health
acquisition.
|
|
|
|
|
|
|
|
|
|
|
2
|
The tax impact
related to special item adjustments reflects the current and
deferred income taxes associated with the above pre-tax special
items in arriving at adjusted earnings.
|
|
Johnson &
Johnson and Subsidiaries
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
Adjusted
Operational Sales Growth
|
THIRD
QUARTER 2021 ACTUAL vs. 2020 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
|
|
|
|
|
|
|
WW As
Reported
|
|
5.3%
|
|
13.8%
|
|
8.0%
|
|
10.7%
|
U.S.
|
|
4.5%
|
|
12.2%
|
|
0.8%
|
|
7.9%
|
International
|
|
5.9%
|
|
15.9%
|
|
15.4%
|
|
13.8%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
1.2
|
|
0.6
|
|
1.0
|
|
0.8
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
2.2
|
|
1.3
|
|
2.1
|
|
1.7
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
4.1%
|
|
13.2%
|
|
7.0%
|
|
9.9%
|
U.S.
|
|
4.5%
|
|
12.2%
|
|
0.8%
|
|
7.9%
|
International
|
|
3.7%
|
|
14.6%
|
|
13.3%
|
|
12.1%
|
|
|
|
|
|
|
|
|
|
General
Surgery
|
|
|
|
|
|
|
|
|
Advanced
Sterilization Products
|
|
|
|
|
|
0.4
|
|
0.1
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
0.8
|
|
0.2
|
|
|
|
|
|
|
|
|
|
Skin Health /
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci Labo -
Sedona
|
|
1.1
|
|
|
|
|
|
0.2
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
2.0
|
|
|
|
|
|
0.4
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.5
|
|
0.6
|
|
0.2
|
|
0.4
|
U.S.
|
|
0.6
|
|
0.0
|
|
0.3
|
|
0.1
|
International
|
|
0.3
|
|
1.4
|
|
0.0
|
|
0.8
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
5.7%
|
|
13.8%
|
|
7.6%
|
|
10.6%
|
U.S.
|
|
5.1%
|
|
12.2%
|
|
1.1%
|
|
8.0%
|
International
|
|
6.1%
|
|
16.0%
|
|
14.1%
|
|
13.5%
|
|
|
|
|
|
|
|
|
|
Note: Percentages are
based on actual, non-rounded figures and may not sum
|
Johnson &
Johnson and Subsidiaries
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
Adjusted
Operational Sales Growth
|
NINE MONTHS
2021 ACTUAL vs. 2020 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
|
|
|
|
|
|
|
WW As
Reported
|
|
5.2%
|
|
13.5%
|
|
23.4%
|
|
14.7%
|
U.S.
|
|
2.8%
|
|
10.3%
|
|
20.6%
|
|
11.7%
|
International
|
|
7.3%
|
|
17.5%
|
|
26.0%
|
|
18.0%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
2.1
|
|
2.2
|
|
2.9
|
|
2.3
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
3.8
|
|
5.0
|
|
5.5
|
|
4.9
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
3.1%
|
|
11.3%
|
|
20.5%
|
|
12.4%
|
U.S.
|
|
2.8%
|
|
10.3%
|
|
20.6%
|
|
11.7%
|
International
|
|
3.5%
|
|
12.5%
|
|
20.5%
|
|
13.1%
|
|
|
|
|
|
|
|
|
|
General
Surgery
|
|
|
|
|
|
|
|
|
Advanced
Sterilization Products
|
|
|
|
|
|
0.6
|
|
0.2
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
1.2
|
|
0.3
|
|
|
|
|
|
|
|
|
|
Skin Health /
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci Labo -
Sedona
|
|
0.5
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
0.9
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.5
|
|
0.5
|
|
0.2
|
|
0.4
|
U.S.
|
|
0.5
|
|
(0.1)
|
|
0.4
|
|
0.1
|
International
|
|
0.3
|
|
1.3
|
|
0.0
|
|
0.7
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
4.1%
|
|
11.8%
|
|
21.4%
|
|
13.1%
|
U.S.
|
|
3.3%
|
|
10.2%
|
|
21.0%
|
|
11.8%
|
International
|
|
4.7%
|
|
13.8%
|
|
21.7%
|
|
14.4%
|
|
|
|
|
|
|
|
|
|
Note:
Percentages are based on actual, non-rounded figures and may not
sum
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER HEALTH
SEGMENT (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
686
|
|
601
|
14.0%
|
14.0%
|
-
|
|
|
$
1,960
|
|
1,917
|
2.2%
|
2.2%
|
-
|
Intl
|
|
686
|
|
541
|
26.9%
|
22.8%
|
4.1%
|
|
|
1,894
|
|
1,722
|
10.0%
|
3.9%
|
6.1%
|
WW
|
|
1,372
|
|
1,142
|
20.1%
|
18.2%
|
1.9%
|
|
|
3,854
|
|
3,639
|
5.9%
|
3.0%
|
2.9%
|
SKIN HEALTH /
BEAUTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
569
|
|
572
|
-0.5%
|
-0.5%
|
-
|
|
|
1,862
|
|
1,767
|
5.4%
|
5.4%
|
-
|
Intl
|
|
555
|
|
577
|
-3.8%
|
-5.5%
|
1.7%
|
|
|
1,595
|
|
1,506
|
5.9%
|
2.1%
|
3.8%
|
WW
|
|
1,124
|
|
1,149
|
-2.2%
|
-3.0%
|
0.8%
|
|
|
3,457
|
|
3,273
|
5.6%
|
3.9%
|
1.7%
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
150
|
|
164
|
-8.4%
|
-8.4%
|
-
|
|
|
478
|
|
510
|
-6.2%
|
-6.2%
|
-
|
Intl
|
|
248
|
|
248
|
0.1%
|
-1.8%
|
1.9%
|
|
|
762
|
|
694
|
9.9%
|
5.9%
|
4.0%
|
WW
|
|
398
|
|
412
|
-3.3%
|
-4.5%
|
1.2%
|
|
|
1,240
|
|
1,204
|
3.0%
|
0.8%
|
2.2%
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
95
|
|
91
|
5.2%
|
5.2%
|
-
|
|
|
288
|
|
279
|
3.3%
|
3.3%
|
-
|
Intl
|
|
296
|
|
302
|
-2.0%
|
-3.1%
|
1.1%
|
|
|
879
|
|
831
|
5.8%
|
4.6%
|
1.2%
|
WW
|
|
391
|
|
393
|
-0.3%
|
-1.2%
|
0.9%
|
|
|
1,167
|
|
1,110
|
5.2%
|
4.3%
|
0.9%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3
|
|
3
|
20.1%
|
20.1%
|
-
|
|
|
9
|
|
10
|
-5.7%
|
-5.7%
|
-
|
Intl
|
|
229
|
|
227
|
0.5%
|
0.6%
|
-0.1%
|
|
|
675
|
|
654
|
3.1%
|
2.3%
|
0.8%
|
WW
|
|
232
|
|
230
|
0.8%
|
0.8%
|
0.0%
|
|
|
684
|
|
664
|
3.0%
|
2.1%
|
0.9%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
122
|
|
125
|
-2.6%
|
-2.6%
|
-
|
|
|
390
|
|
370
|
5.3%
|
5.3%
|
-
|
Intl
|
|
61
|
|
64
|
-5.2%
|
-9.0%
|
3.8%
|
|
|
186
|
|
175
|
5.8%
|
0.0%
|
5.8%
|
WW
|
|
182
|
|
189
|
-3.5%
|
-4.8%
|
1.3%
|
|
|
575
|
|
545
|
5.4%
|
3.6%
|
1.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL CONSUMER
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,625
|
|
1,556
|
4.5%
|
4.5%
|
-
|
|
|
4,987
|
|
4,853
|
2.8%
|
2.8%
|
-
|
Intl
|
|
2,075
|
|
1,958
|
5.9%
|
3.7%
|
2.2%
|
|
|
5,991
|
|
5,582
|
7.3%
|
3.5%
|
3.8%
|
WW
|
|
$
3,700
|
|
3,514
|
5.3%
|
4.1%
|
1.2%
|
|
|
$
10,978
|
|
10,435
|
5.2%
|
3.1%
|
2.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
PHARMACEUTICAL
SEGMENT (2,3)
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
2,771
|
|
2,558
|
8.3%
|
8.3%
|
-
|
|
|
$
7,932
|
|
7,330
|
8.2%
|
8.2%
|
-
|
Intl
|
|
1,480
|
|
1,230
|
20.3%
|
18.8%
|
1.5%
|
|
|
4,464
|
|
3,619
|
23.3%
|
17.6%
|
5.7%
|
WW
|
|
4,250
|
|
3,789
|
12.2%
|
11.7%
|
0.5%
|
|
|
12,395
|
|
10,950
|
13.2%
|
11.3%
|
1.9%
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
480
|
|
634
|
-24.3%
|
-24.3%
|
-
|
|
|
1,508
|
|
1,852
|
-18.6%
|
-18.6%
|
-
|
US Exports
(4)
|
|
47
|
|
78
|
-40.2%
|
-40.2%
|
-
|
|
|
197
|
|
321
|
-38.7%
|
-38.7%
|
-
|
Intl
|
|
234
|
|
209
|
12.2%
|
8.1%
|
4.1%
|
|
|
721
|
|
673
|
7.1%
|
1.4%
|
5.7%
|
WW
|
|
761
|
|
921
|
-17.4%
|
-18.3%
|
0.9%
|
|
|
2,426
|
|
2,846
|
-14.8%
|
-16.1%
|
1.3%
|
SIMPONI / SIMPONI
ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
295
|
|
312
|
-5.3%
|
-5.3%
|
-
|
|
|
840
|
|
840
|
0.0%
|
0.0%
|
-
|
Intl
|
|
276
|
|
280
|
-1.1%
|
-0.7%
|
-0.4%
|
|
|
877
|
|
827
|
6.1%
|
2.8%
|
3.3%
|
WW
|
|
571
|
|
592
|
-3.3%
|
-3.1%
|
-0.2%
|
|
|
1,717
|
|
1,667
|
3.0%
|
1.4%
|
1.6%
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,569
|
|
1,313
|
19.5%
|
19.5%
|
-
|
|
|
4,396
|
|
3,668
|
19.9%
|
19.9%
|
-
|
Intl
|
|
809
|
|
634
|
27.7%
|
26.3%
|
1.4%
|
|
|
2,404
|
|
1,795
|
33.9%
|
27.5%
|
6.4%
|
WW
|
|
2,378
|
|
1,947
|
22.2%
|
21.7%
|
0.5%
|
|
|
6,800
|
|
5,463
|
24.5%
|
22.4%
|
2.1%
|
TREMFYA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
376
|
|
222
|
69.7%
|
69.7%
|
-
|
|
|
975
|
|
650
|
50.1%
|
50.1%
|
-
|
Intl
|
|
161
|
|
105
|
52.5%
|
50.5%
|
2.0%
|
|
|
459
|
|
316
|
45.4%
|
38.0%
|
7.4%
|
WW
|
|
537
|
|
327
|
64.1%
|
63.5%
|
0.6%
|
|
|
1,434
|
|
965
|
48.5%
|
46.1%
|
2.4%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3
|
|
-
|
*
|
*
|
-
|
|
|
15
|
|
-
|
*
|
*
|
-
|
Intl
|
|
0
|
|
3
|
*
|
*
|
*
|
|
|
3
|
|
9
|
-68.6%
|
-70.8%
|
2.2%
|
WW
|
|
3
|
|
3
|
-26.4%
|
-27.5%
|
1.1%
|
|
|
18
|
|
9
|
91.6%
|
89.5%
|
2.1%
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
679
|
|
413
|
64.3%
|
64.3%
|
-
|
|
|
1,635
|
|
1,265
|
29.2%
|
29.2%
|
-
|
Intl
|
|
709
|
|
451
|
57.2%
|
55.6%
|
1.6%
|
|
|
1,788
|
|
1,397
|
28.0%
|
23.2%
|
4.8%
|
WW
|
|
1,389
|
|
864
|
60.6%
|
59.8%
|
0.8%
|
|
|
3,424
|
|
2,662
|
28.6%
|
26.1%
|
2.5%
|
COVID-19
VACCINE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
270
|
|
-
|
*
|
*
|
-
|
|
|
421
|
|
-
|
*
|
*
|
-
|
Intl
|
|
233
|
|
-
|
*
|
*
|
-
|
|
|
346
|
|
-
|
*
|
*
|
-
|
WW
|
|
502
|
|
-
|
*
|
*
|
-
|
|
|
766
|
|
-
|
*
|
*
|
-
|
EDURANT /
rilpivirine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
12
|
|
11
|
8.4%
|
8.4%
|
-
|
|
|
31
|
|
33
|
-4.8%
|
-4.8%
|
-
|
Intl
|
|
247
|
|
226
|
9.7%
|
8.7%
|
1.0%
|
|
|
733
|
|
684
|
7.2%
|
1.7%
|
5.5%
|
WW
|
|
259
|
|
236
|
9.6%
|
8.6%
|
1.0%
|
|
|
764
|
|
716
|
6.7%
|
1.4%
|
5.3%
|
PREZISTA / PREZCOBIX
/ REZOLSTA / SYMTUZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
380
|
|
379
|
0.4%
|
0.4%
|
-
|
|
|
1,128
|
|
1,154
|
-2.2%
|
-2.2%
|
-
|
Intl
|
|
137
|
|
147
|
-7.1%
|
-8.8%
|
1.7%
|
|
|
440
|
|
461
|
-4.6%
|
-8.6%
|
4.0%
|
WW
|
|
517
|
|
526
|
-1.7%
|
-2.2%
|
0.5%
|
|
|
1,568
|
|
1,615
|
-2.9%
|
-4.1%
|
1.2%
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
18
|
|
24
|
-26.0%
|
-26.0%
|
-
|
|
|
55
|
|
79
|
-29.6%
|
-29.6%
|
-
|
Intl
|
|
93
|
|
78
|
18.3%
|
15.2%
|
3.1%
|
|
|
270
|
|
252
|
6.9%
|
2.6%
|
4.3%
|
WW
|
|
110
|
|
102
|
7.8%
|
5.4%
|
2.4%
|
|
|
325
|
|
331
|
-1.8%
|
-5.0%
|
3.2%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
835
|
|
759
|
10.2%
|
10.2%
|
-
|
|
|
2,448
|
|
2,285
|
7.2%
|
7.2%
|
-
|
Intl
|
|
854
|
|
846
|
0.8%
|
-0.5%
|
1.3%
|
|
|
2,770
|
|
2,565
|
8.0%
|
4.1%
|
3.9%
|
WW
|
|
1,689
|
|
1,605
|
5.3%
|
4.6%
|
0.7%
|
|
|
5,218
|
|
4,850
|
7.6%
|
5.5%
|
2.1%
|
CONCERTA /
Methylphenidate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
35
|
|
43
|
-19.5%
|
-19.5%
|
-
|
|
|
117
|
|
150
|
-22.1%
|
-22.1%
|
-
|
Intl
|
|
122
|
|
107
|
14.2%
|
12.5%
|
1.7%
|
|
|
372
|
|
319
|
16.4%
|
11.6%
|
4.8%
|
WW
|
|
157
|
|
149
|
4.5%
|
3.3%
|
1.2%
|
|
|
489
|
|
469
|
4.1%
|
0.8%
|
3.3%
|
INVEGA SUSTENNA /
XEPLION /
INVEGA TRINZA / TREVICTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
648
|
|
585
|
11.0%
|
11.0%
|
-
|
|
|
1,882
|
|
1,704
|
10.4%
|
10.4%
|
-
|
Intl
|
|
355
|
|
341
|
4.3%
|
3.2%
|
1.1%
|
|
|
1,111
|
|
983
|
13.0%
|
7.6%
|
5.4%
|
WW
|
|
1,004
|
|
926
|
8.5%
|
8.1%
|
0.4%
|
|
|
2,994
|
|
2,688
|
11.4%
|
9.4%
|
2.0%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
71
|
|
70
|
1.3%
|
1.3%
|
-
|
|
|
210
|
|
220
|
-4.7%
|
-4.7%
|
-
|
Intl
|
|
69
|
|
81
|
-16.7%
|
-16.0%
|
-0.7%
|
|
|
242
|
|
254
|
-5.1%
|
-8.3%
|
3.2%
|
WW
|
|
140
|
|
152
|
-8.4%
|
-8.0%
|
-0.4%
|
|
|
452
|
|
475
|
-4.9%
|
-6.6%
|
1.7%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
81
|
|
60
|
34.7%
|
34.7%
|
-
|
|
|
239
|
|
210
|
13.9%
|
13.9%
|
-
|
Intl
|
|
307
|
|
317
|
-2.9%
|
-4.8%
|
1.9%
|
|
|
1,045
|
|
1,008
|
3.7%
|
1.5%
|
2.2%
|
WW
|
|
388
|
|
377
|
3.1%
|
1.5%
|
1.6%
|
|
|
1,284
|
|
1,218
|
5.5%
|
3.6%
|
1.9%
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,525
|
|
1,267
|
20.3%
|
20.3%
|
-
|
|
|
4,364
|
|
3,623
|
20.4%
|
20.4%
|
-
|
Intl
|
|
2,140
|
|
1,862
|
14.9%
|
13.8%
|
1.1%
|
|
|
6,406
|
|
5,310
|
20.6%
|
15.3%
|
5.3%
|
WW
|
|
3,665
|
|
3,129
|
17.1%
|
16.5%
|
0.6%
|
|
|
10,770
|
|
8,933
|
20.6%
|
17.4%
|
3.2%
|
DARZALEX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
841
|
|
585
|
43.7%
|
43.7%
|
-
|
|
|
2,302
|
|
1,540
|
49.5%
|
49.5%
|
-
|
Intl
|
|
739
|
|
514
|
43.7%
|
42.0%
|
1.7%
|
|
|
2,076
|
|
1,397
|
48.6%
|
42.2%
|
6.4%
|
WW
|
|
1,580
|
|
1,099
|
43.7%
|
42.9%
|
0.8%
|
|
|
4,378
|
|
2,937
|
49.1%
|
46.0%
|
3.1%
|
ERLEADA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
214
|
|
152
|
40.5%
|
40.5%
|
-
|
|
|
578
|
|
407
|
41.8%
|
41.8%
|
-
|
Intl
|
|
130
|
|
55
|
*
|
*
|
*
|
|
|
329
|
|
112
|
*
|
*
|
*
|
WW
|
|
344
|
|
206
|
66.7%
|
65.8%
|
0.9%
|
|
|
907
|
|
519
|
74.7%
|
72.2%
|
2.5%
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
413
|
|
450
|
-8.3%
|
-8.3%
|
-
|
|
|
1,311
|
|
1,329
|
-1.3%
|
-1.3%
|
-
|
Intl
|
|
654
|
|
581
|
12.6%
|
10.9%
|
1.7%
|
|
|
1,996
|
|
1,682
|
18.7%
|
13.1%
|
5.6%
|
WW
|
|
1,066
|
|
1,031
|
3.5%
|
2.5%
|
1.0%
|
|
|
3,307
|
|
3,011
|
9.9%
|
6.7%
|
3.2%
|
ZYTIGA / abiraterone
acetate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
25
|
|
58
|
-57.0%
|
-57.0%
|
-
|
|
|
96
|
|
284
|
-66.2%
|
-66.2%
|
-
|
Intl
|
|
523
|
|
532
|
-1.8%
|
-2.1%
|
0.3%
|
|
|
1,653
|
|
1,564
|
5.7%
|
0.9%
|
4.8%
|
WW
|
|
548
|
|
590
|
-7.2%
|
-7.5%
|
0.3%
|
|
|
1,749
|
|
1,848
|
-5.4%
|
-9.4%
|
4.0%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
32
|
|
21
|
49.6%
|
49.6%
|
-
|
|
|
76
|
|
63
|
21.0%
|
21.0%
|
-
|
Intl
|
|
94
|
|
181
|
-48.0%
|
-47.2%
|
-0.8%
|
|
|
352
|
|
556
|
-36.6%
|
-38.5%
|
1.9%
|
WW
|
|
126
|
|
203
|
-37.6%
|
-36.9%
|
-0.7%
|
|
|
428
|
|
619
|
-30.7%
|
-32.4%
|
1.7%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
610
|
|
510
|
19.7%
|
19.7%
|
-
|
|
|
1,778
|
|
1,541
|
15.4%
|
15.4%
|
-
|
Intl
|
|
258
|
|
239
|
7.9%
|
8.4%
|
-0.5%
|
|
|
821
|
|
742
|
10.7%
|
7.3%
|
3.4%
|
WW
|
|
868
|
|
749
|
15.9%
|
16.1%
|
-0.2%
|
|
|
2,599
|
|
2,283
|
13.9%
|
12.7%
|
1.2%
|
OPSUMIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
299
|
|
244
|
22.8%
|
22.8%
|
-
|
|
|
861
|
|
729
|
18.2%
|
18.2%
|
-
|
Intl
|
|
159
|
|
148
|
7.4%
|
7.8%
|
-0.4%
|
|
|
510
|
|
458
|
11.3%
|
7.7%
|
3.6%
|
WW
|
|
458
|
|
392
|
17.0%
|
17.1%
|
-0.1%
|
|
|
1,371
|
|
1,187
|
15.5%
|
14.1%
|
1.4%
|
UPTRAVI
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
265
|
|
226
|
17.3%
|
17.3%
|
-
|
|
|
792
|
|
692
|
14.6%
|
14.6%
|
-
|
Intl
|
|
44
|
|
34
|
30.4%
|
28.8%
|
1.6%
|
|
|
135
|
|
100
|
34.6%
|
27.9%
|
6.7%
|
WW
|
|
309
|
|
260
|
19.0%
|
18.8%
|
0.2%
|
|
|
927
|
|
792
|
17.1%
|
16.2%
|
0.9%
|
OTHER PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
47
|
|
40
|
14.4%
|
14.4%
|
-
|
|
|
125
|
|
121
|
2.8%
|
2.8%
|
-
|
Intl
|
|
54
|
|
57
|
-4.4%
|
-2.1%
|
-2.3%
|
|
|
176
|
|
183
|
-3.7%
|
-5.0%
|
1.3%
|
WW
|
|
101
|
|
97
|
3.4%
|
4.8%
|
-1.4%
|
|
|
301
|
|
304
|
-1.1%
|
-1.9%
|
0.8%
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
800
|
|
931
|
-14.0%
|
-14.0%
|
-
|
|
|
2,379
|
|
2,574
|
-7.6%
|
-7.6%
|
-
|
Intl
|
|
333
|
|
351
|
-5.1%
|
-8.2%
|
3.1%
|
|
|
1,007
|
|
1,052
|
-4.2%
|
-9.3%
|
5.1%
|
WW
|
|
1,133
|
|
1,281
|
-11.5%
|
-12.4%
|
0.9%
|
|
|
3,386
|
|
3,625
|
-6.6%
|
-8.1%
|
1.5%
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
636
|
|
630
|
0.8%
|
0.8%
|
-
|
|
|
1,794
|
|
1,716
|
4.5%
|
4.5%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
636
|
|
630
|
0.8%
|
0.8%
|
-
|
|
|
1,794
|
|
1,716
|
4.5%
|
4.5%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
66
|
|
156
|
-57.4%
|
-57.4%
|
-
|
|
|
249
|
|
405
|
-38.4%
|
-38.4%
|
-
|
Intl
|
|
67
|
|
68
|
-1.0%
|
-4.3%
|
3.3%
|
|
|
194
|
|
173
|
11.9%
|
5.8%
|
6.1%
|
WW
|
|
133
|
|
224
|
-40.3%
|
-41.3%
|
1.0%
|
|
|
443
|
|
578
|
-23.4%
|
-25.2%
|
1.8%
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
47
|
|
69
|
-30.9%
|
-30.9%
|
-
|
|
|
168
|
|
215
|
-21.7%
|
-21.7%
|
-
|
Intl
|
|
65
|
|
63
|
3.1%
|
0.5%
|
2.6%
|
|
|
198
|
|
208
|
-4.7%
|
-9.7%
|
5.0%
|
WW
|
|
112
|
|
132
|
-14.6%
|
-15.8%
|
1.2%
|
|
|
366
|
|
423
|
-13.4%
|
-15.8%
|
2.4%
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
51
|
|
75
|
-32.6%
|
-32.6%
|
-
|
|
|
168
|
|
238
|
-29.3%
|
-29.3%
|
-
|
Intl
|
|
200
|
|
219
|
-8.7%
|
-11.9%
|
3.2%
|
|
|
615
|
|
670
|
-8.3%
|
-13.1%
|
4.8%
|
WW
|
|
251
|
|
294
|
-14.8%
|
-17.2%
|
2.4%
|
|
|
783
|
|
908
|
-13.8%
|
-17.3%
|
3.5%
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
7,221
|
|
6,438
|
12.2%
|
12.2%
|
-
|
|
|
20,536
|
|
18,619
|
10.3%
|
10.3%
|
-
|
Intl
|
|
5,773
|
|
4,980
|
15.9%
|
14.6%
|
1.3%
|
|
|
17,256
|
|
14,685
|
17.5%
|
12.5%
|
5.0%
|
WW
|
|
$
12,994
|
|
11,418
|
13.8%
|
13.2%
|
0.6%
|
|
|
$
37,792
|
|
33,304
|
13.5%
|
11.3%
|
2.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
MEDICAL DEVICES
SEGMENT (2)
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INTERVENTIONAL
SOLUTIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
444
|
|
399
|
11.1%
|
11.1%
|
-
|
|
|
1,353
|
|
1,019
|
32.7%
|
32.7%
|
-
|
Intl
|
|
513
|
|
437
|
17.7%
|
15.1%
|
2.6%
|
|
|
1,599
|
|
1,134
|
41.1%
|
34.3%
|
6.8%
|
WW
|
|
957
|
|
836
|
14.5%
|
13.2%
|
1.3%
|
|
|
2,952
|
|
2,153
|
37.1%
|
33.6%
|
3.5%
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,249
|
|
1,308
|
-4.5%
|
-4.5%
|
-
|
|
|
3,821
|
|
3,427
|
11.5%
|
11.5%
|
-
|
Intl
|
|
843
|
|
774
|
8.8%
|
6.8%
|
2.0%
|
|
|
2,611
|
|
2,145
|
21.7%
|
15.4%
|
6.3%
|
WW
|
|
2,093
|
|
2,083
|
0.5%
|
-0.3%
|
0.8%
|
|
|
6,433
|
|
5,572
|
15.4%
|
13.0%
|
2.4%
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
210
|
|
221
|
-5.3%
|
-5.3%
|
-
|
|
|
654
|
|
564
|
15.9%
|
15.9%
|
-
|
Intl
|
|
146
|
|
124
|
18.8%
|
16.0%
|
2.8%
|
|
|
451
|
|
344
|
31.3%
|
24.1%
|
7.2%
|
WW
|
|
356
|
|
345
|
3.3%
|
2.3%
|
1.0%
|
|
|
1,105
|
|
908
|
21.8%
|
19.0%
|
2.8%
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
184
|
|
205
|
-9.8%
|
-9.8%
|
-
|
|
|
579
|
|
527
|
10.0%
|
10.0%
|
-
|
Intl
|
|
131
|
|
102
|
28.1%
|
25.9%
|
2.2%
|
|
|
403
|
|
298
|
35.4%
|
28.2%
|
7.2%
|
WW
|
|
316
|
|
308
|
2.8%
|
2.1%
|
0.7%
|
|
|
983
|
|
825
|
19.2%
|
16.6%
|
2.6%
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
455
|
|
433
|
5.3%
|
5.3%
|
-
|
|
|
1,352
|
|
1,194
|
13.3%
|
13.3%
|
-
|
Intl
|
|
260
|
|
253
|
2.4%
|
0.9%
|
1.5%
|
|
|
805
|
|
698
|
15.2%
|
9.5%
|
5.7%
|
WW
|
|
715
|
|
685
|
4.2%
|
3.7%
|
0.5%
|
|
|
2,157
|
|
1,892
|
14.0%
|
11.9%
|
2.1%
|
SPINE, SPORTS &
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
400
|
|
449
|
-11.1%
|
-11.1%
|
-
|
|
|
1,236
|
|
1,142
|
8.2%
|
8.2%
|
-
|
Intl
|
|
306
|
|
295
|
3.5%
|
1.5%
|
2.0%
|
|
|
952
|
|
805
|
18.2%
|
12.0%
|
6.2%
|
WW
|
|
705
|
|
745
|
-5.3%
|
-6.1%
|
0.8%
|
|
|
2,187
|
|
1,947
|
12.3%
|
9.7%
|
2.6%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2021
|
|
2020
|
Reported
|
Operational
(1)
|
Currency
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
948
|
|
913
|
3.9%
|
3.9%
|
-
|
|
|
2,881
|
|
2,247
|
28.2%
|
28.2%
|
-
|
Intl
|
|
1,457
|
|
1,239
|
17.6%
|
14.8%
|
2.8%
|
|
|
4,418
|
|
3,556
|
24.2%
|
18.4%
|
5.8%
|
WW
|
|
2,405
|
|
2,152
|
11.8%
|
10.2%
|
1.6%
|
|
|
7,299
|
|
5,803
|
25.8%
|
22.2%
|
3.6%
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
440
|
|
421
|
4.6%
|
4.6%
|
-
|
|
|
1,304
|
|
1,079
|
20.9%
|
20.9%
|
-
|
Intl
|
|
705
|
|
579
|
21.8%
|
18.4%
|
3.4%
|
|
|
2,126
|
|
1,644
|
29.3%
|
23.1%
|
6.2%
|
WW
|
|
1,144
|
|
1,000
|
14.6%
|
12.6%
|
2.0%
|
|
|
3,430
|
|
2,723
|
26.0%
|
22.2%
|
3.8%
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
508
|
|
492
|
3.3%
|
3.3%
|
-
|
|
|
1,577
|
|
1,168
|
35.0%
|
35.0%
|
-
|
Intl
|
|
752
|
|
660
|
13.9%
|
11.7%
|
2.2%
|
|
|
2,292
|
|
1,912
|
19.9%
|
14.5%
|
5.4%
|
WW
|
|
1,261
|
|
1,152
|
9.4%
|
8.1%
|
1.3%
|
|
|
3,869
|
|
3,080
|
25.6%
|
22.3%
|
3.3%
|
VISION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
475
|
|
473
|
0.6%
|
0.6%
|
-
|
|
|
1,414
|
|
1,160
|
21.9%
|
21.9%
|
-
|
Intl
|
|
714
|
|
608
|
17.4%
|
17.4%
|
0.0%
|
|
|
2,103
|
|
1,683
|
25.0%
|
22.0%
|
3.0%
|
WW
|
|
1,189
|
|
1,081
|
10.1%
|
10.0%
|
0.1%
|
|
|
3,517
|
|
2,843
|
23.7%
|
22.0%
|
1.7%
|
CONTACT LENSES /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
359
|
|
375
|
-4.3%
|
-4.3%
|
-
|
|
|
1,082
|
|
924
|
17.0%
|
17.0%
|
-
|
Intl
|
|
522
|
|
455
|
14.9%
|
15.2%
|
-0.3%
|
|
|
1,525
|
|
1,274
|
19.8%
|
17.3%
|
2.5%
|
WW
|
|
882
|
|
830
|
6.2%
|
6.4%
|
-0.2%
|
|
|
2,607
|
|
2,198
|
18.6%
|
17.2%
|
1.4%
|
SURGICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
117
|
|
98
|
19.6%
|
19.6%
|
-
|
|
|
333
|
|
236
|
41.1%
|
41.1%
|
-
|
Intl
|
|
191
|
|
153
|
24.7%
|
23.7%
|
1.0%
|
|
|
577
|
|
409
|
41.1%
|
36.7%
|
4.4%
|
WW
|
|
308
|
|
251
|
22.7%
|
22.1%
|
0.6%
|
|
|
910
|
|
645
|
41.1%
|
38.3%
|
2.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,117
|
|
3,092
|
0.8%
|
0.8%
|
-
|
|
|
9,470
|
|
7,852
|
20.6%
|
20.6%
|
-
|
Intl
|
|
3,527
|
|
3,058
|
15.4%
|
13.3%
|
2.1%
|
|
|
10,731
|
|
8,518
|
26.0%
|
20.5%
|
5.5%
|
WW
|
|
$
6,644
|
|
6,150
|
8.0%
|
7.0%
|
1.0%
|
|
|
$
20,201
|
|
16,370
|
23.4%
|
20.5%
|
2.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note: Columns
and rows within tables may not add due to rounding. Percentages
have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100% or not meaningful
|
(1) Operational
growth excludes the effect of translational currency
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
(3) Certain prior
year amounts have been reclassified to conform to current year
product disclosures
|
|
|
|
|
|
|
|
|
|
|
(4) Reported as U.S.
sales
|
|
|
|
|
|
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-reports-q3-2021-results-301402807.html
SOURCE Johnson & Johnson